Atazanavir (Reyetaz®), an azapeptide class of protease inhibitors, was approved by the US FDA for use in HIV infection on June 20, 2003. Atazanavir (ATV) has a unique pharmacokinetic profile allowing for once-daily dosing, which is optimized when taken with food.
Azithromycin administration to patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection was associated with a reduction in number of exacerbations, improvement in airflow, and weight gain.
By determining whether 4 key risk factors are present, clinicians might be able to identify those patients with S aureus bacteremia who are at increased risk of serious, complicated infection.
Inactivated trivalent influenza vaccine did not reduce the incidence of acute otitis media among children 6-24 months of age.
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
The objective of this monograph is to provide an overview of the scope of allergic disorders, and review the current understanding of the mechanism of the allergic response. Due to the extensive nature of the topic, we will limit our discussion to systemic reactions eliciting an IgE-mediated response. Further, the intimate relationship between organs involved will be reviewed, particularly the relationship between allergic rhinitis and asthma. Part I includes the current evaluation, including historical features, exposures, physical exam findings, and ancillary diagnostic options will be reviewed.